North East and North Cumbria
ICS Formulary
 
back
6 Endocrine system
06-07-02 Drugs affecting gonadotrophins

Northern Region Gender Dysphoria Service

General Guidelines For The Use Of Hormone Treatment In Gender Dysphoria


Leuprorelin
First Choice
  • Approved formualtions include 3.75mg and 11.25mg pre filled syringes (also see section 8.3.4.2).

Green plus View adult BNF  View SPC online  View childrens BNF
Relugolix–estradiol–norethisterone acetate Ryeqo®
Formulary
  • Approved as an option for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age - in line with NICE TA832.
Link  NICE TA832: Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids

Green plus View adult BNF  View SPC online  View childrens BNF
Buserelin 150microgram nasal spray
Formulary

Green View adult BNF  View SPC online  View childrens BNF
Cetrorelix
Formulary

Red View adult BNF  View SPC online  View childrens BNF
Danazol 100mg and 200mg capsules
Formulary

Green View adult BNF  View SPC online  View childrens BNF
Goserelin
Formulary
  • The following goserelin formulations are approved for use 3.6mg & 10.8mg injections (also see section 8.3.4.2). 
  • Note: leuprorelin is now substantially less expensive than goserelin

Green plus View adult BNF  View SPC online  View childrens BNF
Nafarelin
Formulary

Green plus View adult BNF  View SPC online  View childrens BNF
Triptorelin
Formulary
  • The following formulations are approved for use in treating precocious puberty:
    • Gonapeptyl Depot® 3.75mg injection;
    • Decapeptyl SR®11.25mg injection.

  • Refer to Chapter 8 - Gonadorelin analogues for the treatment of prostate cancer. The following strengths are approved:
    • 3mg, 11.25mg and 22.5mg

 

Green plus View adult BNF  View SPC online  View childrens BNF